Inhibiting multiple forms of cell death optimizes ganglion cells survival after retinal ischemia reperfusion injury.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
30 05 2022
Historique:
received: 29 11 2021
accepted: 03 05 2022
revised: 27 04 2022
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 3 6 2022
Statut: epublish

Résumé

Progressive retinal ganglion cells (RGCs) death that triggered by retinal ischemia reperfusion (IR), leads to irreversible visual impairment and blindness, but our knowledge of post-IR neuronal death and related mechanisms is limited. In this study, we first demonstrated that apart from necroptosis, which occurs before apoptosis, ferroptosis, which is characterized by iron deposition and lipid peroxidation, is involved in the whole course of retinal IR in mice. Correspondingly, all three types of RGCs death were found in retina samples from human glaucoma donors. Further, inhibitors of apoptosis, necroptosis, and ferroptosis (z-VAD-FMK, Necrostatin-1, and Ferrostatin-1, respectively) all exhibited marked RGC protection against IR both in mice and primary cultured RGCs, with Ferrostatin-1 conferring the best therapeutic effect, suggesting ferroptosis plays a more prominent role in the process of RGC death. We also found that activated microglia, Müller cells, immune responses, and intracellular reactive oxygen species accumulation following IR were significantly mitigated after each inhibitor treatment, albeit to varying degrees. Moreover, Ferrostatin-1 in combination with z-VAD-FMK and Necrostatin-1 prevented IR-induced RGC death better than any inhibitor alone. These findings stand to advance our knowledge of the post-IR RGC death cascade and guide future therapy for RGC protection.

Identifiants

pubmed: 35637215
doi: 10.1038/s41419-022-04911-9
pii: 10.1038/s41419-022-04911-9
pmc: PMC9151775
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

507

Informations de copyright

© 2022. The Author(s).

Références

Pharmacol Res. 2018 Dec;138:16-24
pubmed: 30077733
Oxid Med Cell Longev. 2021 Aug 14;2021:9912436
pubmed: 34426760
Mol Neurodegener. 2020 Apr 15;15(1):26
pubmed: 32295623
Nature. 2019 Nov;575(7784):693-698
pubmed: 31634899
Drug Des Devel Ther. 2014 Mar 21;8:327-39
pubmed: 24711693
Cell. 1997 Nov 14;91(4):479-89
pubmed: 9390557
Exp Eye Res. 2019 Apr;181:316-324
pubmed: 30171859
Proteomics. 2019 Sep;19(18):e1800311
pubmed: 30888116
J Neuroinflammation. 2021 Aug 26;18(1):186
pubmed: 34446062
Redox Biol. 2016 Aug;8:98-109
pubmed: 26773873
Exp Eye Res. 2014 Jun;123:1-7
pubmed: 24751757
Cells. 2021 Sep 16;10(9):
pubmed: 34572088
Immunol Rev. 2020 Sep;297(1):26-38
pubmed: 32729116
J Neurosci. 2000 Dec 1;20(23):8693-700
pubmed: 11102475
Cell Death Differ. 2010 Nov;17(11):1751-9
pubmed: 20489729
J Pharmacol Sci. 2021 Mar;145(3):262-267
pubmed: 33602506
Stroke. 1998 Feb;29(2):487-92; discussion 493
pubmed: 9472894
Oxid Med Cell Longev. 2019 Jun 10;2019:3150145
pubmed: 31281572
Cell Mol Immunol. 2021 May;18(5):1106-1121
pubmed: 33785842
Oxid Med Cell Longev. 2021 Oct 23;2021:5005136
pubmed: 34725564
Cold Spring Harb Protoc. 2013 Jul 01;2013(7):643-52
pubmed: 23818667
Prog Retin Eye Res. 2004 Jan;23(1):91-147
pubmed: 14766318
Drug Discov Today. 2005 Feb 15;10(4):267-73
pubmed: 15708745
Cell Death Differ. 2018 Jan;25(1):180-189
pubmed: 28885615
JCI Insight. 2017 Apr 6;2(7):e90777
pubmed: 28405617
Nat Commun. 2021 Jul 20;12(1):4402
pubmed: 34285231
Invest Ophthalmol Vis Sci. 2011 Apr 20;52(5):2577-83
pubmed: 21282567
Cell Death Differ. 2014 Nov;21(11):1709-20
pubmed: 24902902
Prog Retin Eye Res. 2016 Mar;51:1-40
pubmed: 26113209
Nat Rev Neurosci. 2019 Jan;20(1):19-33
pubmed: 30467385
Nature. 2020 Jan;577(7788):109-114
pubmed: 31827280
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Exp Eye Res. 2020 Apr;193:107961
pubmed: 32045598
Int Immunopharmacol. 2020 Nov;88:106989
pubmed: 33182069
Front Oncol. 2017 Dec 19;7:303
pubmed: 29312883
J Anesth. 2014 Apr;28(2):235-41
pubmed: 24113863
Mediators Inflamm. 2020 Oct 24;2020:7059304
pubmed: 33162831
Nature. 2011 Mar 24;471(7339):S5-7
pubmed: 21430719
Cell Rep. 2020 Mar 10;30(10):3411-3423.e7
pubmed: 32160546
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4049-59
pubmed: 15505055
Neurosci Bull. 2021 Apr;37(4):535-549
pubmed: 33421025
Front Cell Infect Microbiol. 2019 Nov 26;9:406
pubmed: 31850239
Brain Behav Immun. 2021 Mar;93:312-321
pubmed: 33444733
Protein Cell. 2021 Aug;12(8):599-620
pubmed: 33000412
Nature. 2015 Apr 2;520(7545):57-62
pubmed: 25799988
J Biol Chem. 2021 Jan-Jun;296:100187
pubmed: 33334878
Cell Death Dis. 2020 Feb 3;11(2):88
pubmed: 32015325
Cell Biol Int. 2019 Oct;43(10):1201-1204
pubmed: 30811086
Redox Biol. 2021 Jul;43:101984
pubmed: 33933882
J Exp Med. 1998 Sep 7;188(5):979-84
pubmed: 9730899
Curr Mol Med. 2008 May;8(3):207-20
pubmed: 18473820
Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):30
pubmed: 34283208
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Nat Neurosci. 2010 Apr;13(4):411-3
pubmed: 20305648

Auteurs

Qiyu Qin (Q)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Naiji Yu (N)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Yuxiang Gu (Y)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Weishaer Ke (W)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Qi Zhang (Q)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Xin Liu (X)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China.

Kaijun Wang (K)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China. ze_wkj@zju.edu.cn.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China. ze_wkj@zju.edu.cn.

Min Chen (M)

Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China. chenmineye@zju.edu.cn.
Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, Zhejiang Province, China. chenmineye@zju.edu.cn.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH